BI 765049

BI-765049 · Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for BI 765049, covering 2026-02-02 to 2026-04-14. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 [Phase 1]

See pricing